Clepio Biotech has been selected to participate in Toscana Tech on the Road 2026, an internationalization program promoted by Regione Toscana that will bring 15 innovative Tuscan companies to San Francisco from September 28 to October 2, 2026.

The initiative will take place at Casa Toscana, hosted at INNOVIT - Italian Innovation and Culture Hub, and is designed to connect Tuscan innovation with the Silicon Valley ecosystem through meetings with investors, companies and international stakeholders.

Clepio was selected in the biotechnology sector, reflecting the company’s work at the intersection of advanced microscopy, 3D histology and AI-powered image analysis.

Clepio is developing an automated 3D histology platform designed to transform biological specimens into high-resolution digital 3D representations and quantitative data. By combining tissue clearing and labeling, light-sheet fluorescence microscopy and AI-based analysis, the technology aims to provide a more comprehensive view of tissue architecture than conventional two-dimensional approaches.

Participation in Toscana Tech on the Road comes at an important stage in Clepio’s development as the company advances its technology toward industrialization, validation and future clinical applications.

During the week in San Francisco, the Clepio team will have the opportunity to present its technology and vision, engage with the international innovation ecosystem and explore opportunities for investment, strategic partnerships and collaboration.

Clepio Biotech will be in San Francisco from September 28 to October 2.

We look forward to connecting with investors, industry partners and organizations working across biotechnology, digital pathology, advanced imaging and AI for healthcare.

On July 20th, Clepio Biotech welcomed the partners of the European project 3D PATH to its headquarters in Sesto Fiorentino for the M15 Technical Consortium Meeting. The hybrid meeting brought together representatives from ACMIT, who attended in person, and the University of Bern, who joined remotely.

The meeting marked an important milestone in the project, focusing on the technical progress achieved over the first 15 months and the next steps towards the completion of the 3D pathology platform. A key topic of discussion was the hardware design freeze, which incorporated valuable feedback from the University of Bern as future clinical end user.

The consortium also carried out a dedicated risk assessment session, reviewing both technical and operational aspects to ensure a smooth transition into the next development phase. Finally, partners coordinated upcoming activities and aligned priorities to keep the project on track.

Hosting the consortium at our headquarters was an excellent opportunity to strengthen collaboration and reaffirm our shared commitment to bringing next-generation 3D digital pathology closer to clinical practice and precision medicine.

Clepio Biotech was pleased to be hosted by ASMN IRCCS Reggio Emilia for a workshop dedicated to the future of 3D digital pathology and its potential impact on clinical practice.

During the meeting, the Clepio team presented its proprietary technology for generating high-resolution 3D digital tissue twins, illustrating how volumetric imaging and AI-ready datasets can support a new generation of pathology workflows. The discussion focused on the opportunities offered by 3D tissue analysis to overcome the intrinsic sampling bias of conventional histology and improve quantitative assessment of tissue biomarkers.

The workshop also provided an excellent opportunity to exchange ideas with pathologists and clinical researchers, collecting valuable feedback on current challenges in pathology and exploring future applications of Clepio's technology in routine diagnostics.

We sincerely thank the ASMN IRCCS team for their hospitality, their enthusiasm, and the exciting scientific discussions. Collaborations between technology developers and clinical experts are essential to accelerate the translation of innovation into better healthcare solutions.

Clepio Biotech participated in the European Innovation Council (EIC) Summit 2026 in Brussels, one of Europe's leading events dedicated to breakthrough innovation, deep-tech entrepreneurship, and technology transfer.

As coordinator of the EIC Transition project 3D PATH, Clepio had the opportunity to engage with innovators, investors, researchers, policymakers, and industry leaders across Europe. The event provided us a valuable platform to discuss the future of digital pathology, artificial intelligence, and precision medicine.

Through 3D PATH, Clepio is developing technologies that enable the generation of high-resolution 3D digital tissue twins, overcoming the limitations of conventional 2D histology and creating new opportunities for more reliable AI-driven diagnostic tools.

Participation in the EIC Summit reinforces Clepio’s commitment to translating cutting-edge scientific innovation into impactful healthcare solutions and strengthening collaborations within the European innovation ecosystem.

Clepio Biotech participated in the 4th edition of the AI for Oncology and Cancer Research conference in Milan within the framework of the European project 3D PATH.

During the event, the team presented the poster “A novel 3D tissue twin technology enabling new AI for precision medicine”, showcasing Clepio’s approach to creating high-resolution 3D digital tissue twins using advanced light-sheet microscopy.

The technology enables the reconstruction of intact tissue samples with single-cell resolution, overcoming some of the limitations of traditional 2D histopathology and opening new opportunities for the development of more robust AI models for precision oncology.

The conference represented an important opportunity to share the vision of the 3D PATH project, connect with researchers and clinicians, and discuss how volumetric imaging and AI can contribute to the future of personalized cancer treatment.

Clepio Biotech is expanding its visibility on the international stage with an upcoming feature on BFM Business, one of France’s leading business and technology media platforms.

Our CEO, Taiana Deodato, was recently interviewed on the program Trajectoire, which showcases innovative companies and forward-looking leaders shaping the future of technology and industry.

The interview highlights Clepio’s vision in 3D histology and spatial biology, emphasizing the role of advanced imaging and data analysis in transforming biomedical research and digital pathology.

This media appearance represents an important step in strengthening Clepio’s positioning within the European innovation ecosystem and increasing awareness of its cutting-edge technologies.

Clepio Biotech is participating in the XXV Congress of Human Histology and Embryology in Siena, a key event bringing together experts in histology, embryology, and biomedical research.

During the congress, Clepio is presenting its 3D digital pathology solutions and services, combining advanced tissue clearing, light-sheet imaging, and quantitative spatial analysis to enable deeper insights into complex biological systems.

We invite researchers, clinicians, and industry professionals to visit our booth and explore opportunities for collaboration and future projects.

Clepio Biotech is participating in European Congress on Digital Pathology 2025 (ECDP 2025) in Barcelona, one of the leading events for innovation in digital and integrative pathology.

Our team is presenting Clepio’s 3D Histology solutions, presenting how advanced light-sheet imaging and spatial analysis are transforming the way biological samples are explored and interpreted. Our scientific contribution to the conference includes both an oral presentation and a poster session, highlighting recent advances in high-resolution, volumetric imaging for cancer research. In particular, our work focuses on enhancing 3D sample analysis through optimized protocols and multi-confocal light-sheet microscopy approaches.

This participation reinforces Clepio’s role as a key player in the evolution of digital pathology.

Clepio Biotech has been selected for funding under the European Innovation Council (EIC) Transition program, supporting breakthrough technologies on their path from lab to market.

The 3D PATH project, developed in collaboration with ACMIT GmbH and the research group led by Inti Zlobec at the University of Bern, aims to advance the analysis of biological samples through next-generation 3D approaches.

By combining cutting-edge imaging and computational analysis, the project will enable more accurate and spatially resolved insights into complex biological systems, overcoming the limitations of traditional 2D histology.

This milestone reinforces Clepio’s positioning in spatial biology and 3D histology, and marks a key step toward translating advanced research into scalable, real-world applications.

After a long preparation period, finally Clepio Biotech has been incorporated as a company! Our journey in the real world begins, as we can start offering our services for research purposes.

Having won the StartCup Toscana 2023, Clepio Biotech takes part to PNI Cube 2023 in Milan. A vibrant environment, full of startups working in all different fields. A great opportunity to expand our network!

We were present at the 2023 edition of Meet in Italy for Life Sciences in Milan. There, we were awarded a special prize from R&P Legal and Tax, offering free legal consultancy services for our startup.

Clepio Biotech has been awarded the first prize at the regional startup competition StartCup Toscana 2023, held in Pisa. In addition, we got a special prize from the Incubator of the Polo Tecnologico di Navacchio, offering free incubation services for one year.

By winning this award, our team is selected for the nationwide competition Premio Nazionale dell'Innovazione, which will be held in Milan at the end of November.

Sant'Anna news

University of Florence news

La Repubblica